Lithuanian CDMO to open facility in Boston 25-May-2022 By Jane Byrne Northway Biotech, a contract development and manufacturing organization (CDMO) based out of Vilnius, Lithuania, is set to open a facility in Boston, US.
The complete package: Sartorius Stedim adds cell bank manufacture 12-Aug-2019 By Maggie Lynch Sartorius Stedim to offer the GMP manufacture of mammalian cell banks for the biopharmaceutical industry alongside characterization services.
CRISPR research deal will attract new business, says Oxford Genetics 09-Aug-2018 By Flora Southey Oxford Genetics has signed a supply and licensing agreement for CRISPR engineered mammalian cell line with an unnamed ecommerce firm.
Inflectra-maker Celltrion to expand biosimilar capacity by 170,000L 27-May-2016 By Dan Stanton Celltrion will invest $275m at its biosimilar production site in Korea to ramp up capacity from 140,000L to 310,000L by 2021.
Samsung Biologics doubling capacity through third Korean plant 01-Dec-2015 By Dan Stanton Samsung Biologics has invested $740m to build a third facility in Korea, adding a further 180,000L of mammalian cell culture capacity.
Catalent and Toyobo team up to launch GPEx in Japan Catalent and Toyobo team up to launch GPEx in Japan 21-Sep-2011 By Natalie Morrison Catalent has struck up a deal with Toyobo Biologics to launch its cell line engineering technology on the Japanese market.